The BTKi-SLE Study is a global clinical research study looking at an investigational medication for people with SLE.
The study will enroll about 432 people with SLE at approximately 168 study centers in 18 countries around the world.
See if you may pre-qualify - take the pre-screener questionnaire
Systemic lupus erythematosus, commonly referred to as lupus or SLE, is an autoimmune disease. This means that the immune system (which normally protects the body from infections) mistakenly attacks healthy cells. People with lupus may have symptoms in and damage to the affected parts of the body, such as the skin, joints, kidneys, brain and other organs.
By participating in the BTKi-SLE Study, you will help researchers better understand the safety of the investigational medication and how well it works, including its effects on the symptoms of SLE, such as tiredness, joint and muscle pain and skin rash. Researchers will also determine which dose is most effective at reducing SLE symptoms.
The investigational medication works differently than other standard medicines used to treat SLE. People who participate in the BTKi-SLE Study will continue taking their current SLE medications and will also take either the investigational medication or placebo (which looks the same as the investigational medication but contains no actual medication).
You may choose to stop participating in this clinical research study at any time, for any reason. The study doctor and staff are available to discuss any concerns or questions you may have before you decide to participate.
Learn more about the investigational medication